14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
INBX vs DMAC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). INBX carries a Unified Composite Score of 51.4/100 (HOLD) at $77.32 (N/M Forward P/E, 0.0% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (51.4/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (4–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
Technical & Structure Timing Caution: INBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ INBX vs DMAC Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). INBX carries a Unified Composite Score of 51.4/100 (HOLD) at $77.32 (N/M Forward P/E, 0.0% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (51.4/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (4–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: INBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DMAC leads the Growth & Scale pillar: INBX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 4-period historical trajectory (FY2018 to FY2025), INBX cumulative revenue shifted N/A while DMAC shifted N/A. In operating R&D and SG&A reinvestment, INBX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.
INBX and DMAC trade at balanced relative valuation multiples. INBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INBX (-1773.6% ROE) versus DMAC (-114.6% ROE) capital efficiency.
In options market volatility and institutional positioning, INBX carries 116.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.53β · 120% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.